BeiGene Q3 global revenue hits $1.9B, raises full-year guidance to $6.9–7.0B

TREE NEWS update: BeiGene reported third-quarter 2026 global revenue of $1.9 billion, up 34% year over year, with Brukinsa (zanubrutinib) contributing $1.4 billion, also up 34%. GAAP diluted earnings per ADS were $3.28 and non-GAAP diluted earnings per ADS were $4.59. The company raised its full-year 2026 revenue guidance to $6.9–7.0 billion, with GAAP operating income of $1.2–1.3 billion and non-GAAP operating income of $1.9–2.0 billion.